Summary Testosterone-induced DNA synthesis in cultured rat ventral prostate was used to compare the direct effects of EstracytR and EmcytR with that of their metabolite, estramustine, and their carrier-hormone, oestradiol-17/ on prostatic growth. In serum-supplemented medium (5-20% FCS), all the compounds were equally effective in suppressing testosterone stimulated DNA synthesis which was reduced by between 40-50%, whereas in serum-free medium the estramustine compounds were consistently less effective than oestradiol-17,B. In the presence of 4 x 10 -9M testosterone in serum-free medium, stimulated DNA synthesis was reduced by 15-30% following incubation with 4 x 10-7 M of EstracytR, EmcytR and estramustine and by 60% with 4 x 10-7 M oestradiol-17f3. Thus, none of the estramustine compounds appear to offer any selective advantage over that of oestradiol-17/1 in suppressing prostatic DNA synthesis at the target tissue level.
Prostatic cancer is the most common malignancy of the male urogenital tract and a leading cause of death due to cancer in aging men (Chisholm, 1981; Flanders, 1984) . As conventional oestrogen therapy for prostatic cancer is not curative, several new drugs have recently been developed in an attempt to enhance tumour selectivity of chemotherapeutic agents and thereby improve the clinical management of prostatic cancer patients. Among these, the hormone-cytotoxic agent EstracytR (estramustine phosphate; EmCytR, estramustine phosphate disodium) has been extensively investigated for use in the treatment of prostatic cancer (Jonsson & Hogberg, 1971 ; Edsmyr et al., 1982; Hoisaeter & Bakke, 1983; Murphy et al., 1983; Walzer et al., 1984) . The rationale for Estracyt therapy is based on the concept that the hormonal moiety of the drug complex, oestradiol-17/1, would impart tissue specificity by interacting with steroid hormone receptors in the prostate and thus result in a selective accumulation of the alkylating agent, a nor-nitrogen mustard, within the target tissue. Yet, despite both clinical and experimental investigations, the mechanism of action of Estracyt remains unknown (Tew, 1983; Hoisaeter, 1984) .
In both the rat (Plym-Forshell & Nilsson, 1974; Hoisaeter, 1976a Hoisaeter, , 1977 Hoisaeter & Bakke, 1983) and man (PlymForshell et al., 1976; Sandberg, 1983) , Estracyt is rapidly dephosphorylated to yield estramustine and its dehydrogenated counterpart, estromustine. These metabolites are selectively retained in the prostate by interactions with estramustine binding protein (Forsgren et al., 1979 (Forsgren et al., , 1981 Bjork et al., 1982) and subsequent intracellular hydrolysis of these compounds slowly liberates free nitrogen mustard and oestrogen moieties. However, the question remains whether the antiprostatic actions of Estracyt are mediated by the oestrogen moiety, the nitrogen mustard moiety or the intact drug complex itself.
While in vivo studies have shown that Estracyt is a more potent inhibitor of rat prostatic DNA synthesis than either its hormone or cytostatic parts (Hoisaeter, 1976b (Hoisaeter, , 1977 , such comparisons are limited by the extensive metabolism of Estracyt in vivo. Thus, in the present study, an in vitro model of induced DNA synthesis in cultured rat ventral prostate (Mistry et al., 1982; Buchanan & Riches, 1985 , 1986 
Materials and methods
Organ culture Ventral prostate from young adult Wistar rats (4-6 months old) was maintained in serum free and serum-supplemented (5, 10 or 20% foetal calf serum) organ culture for 4 days (Riches et al., 1976; Mistry et al., 1982; Buchanan & Riches, 1985 , 1986 
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During the final 24h of the culture period, each culture was labelled with 37KBq (ljCi) of '25lododeoxyuridine (I-UdR: specific activity 185 GBq mg-', Amersham) as previously described (Mistry et al., 1982) . The explants were then fixed in Bouins fluid, washed in 70% alcohol and weighed (Riches et al., 1976 Figure 1 illustrates the effects of 4 x 10-I M Extracyt, estramustine and oestradiol-17/3 on the proliferative response of rat ventral prostate to 4 x 10-6M testosterone following four days of organ culture in medium containing 0, 5, 10 or 20% foetal calf serum. I-UdR uptakes are normalised to the 0% FCS and testosterone-stimulated measurements. In serum-free medium, only oestradiol-17/3 significantly (P<0.01) inhibited the proliferative response to testosterone. Estracyt was not significantly inhibitory in serum free cultures (P>0.05). However, in serum supplemented media, the estramustine compounds and oestradiol-17/3 all reduced the testosterone response to the level of the unstimulated controls.
10 . Histology Normal rat ventral prostate consists of tubuloalveolar glands which are lined by a single layer of columnar epithelial cells (Figure 2A ). Cultures maintained in serumsupplemented medium without testosterone underwent epithelial atrophy, whereas the addition of 4x 10x6M testosterone maintained the height and secretory activity of the alveolar epithelium and promoted epithelial cell proliferation ( Figure 2B ). Similar cultures treated with testosterone and 4 x 10-I M Estracyt ( Figure 2C ) or estramustine exhibited extensive necrosis of the alveolar epithelium, whereas treatment with 4x 10-M oestradiol-17/ caused marked epithelial atrophy ( Figure 2D ). In serum-free medium, cultures maintained in the absence of testosterone were atrophic, whereas supplementation with 4 x 10-6 M testosterone preserved the normal morphology and secretory activity of the epithelium ( Figure 3A) . Similar cultures treated with 4 x 10 -6 M testosterone and 4 x 10 -S M Estracyt ( Figure 3B ) or estramustine also exhibited wellmaintained alveolar epithelium. In contrast, treatment with 4 x 10 M oestradiol-17/3 was cytotoxic causing widespread necrosis of the alveolar epithelium and fibromuscular stroma ( Figure 3C ). Effects of concentration I-UdR uptake The effects of 4x 10-9, 4x 10 and 4 x 10 -M Estracyt, Emcyt, estramustine and oestradiol-17,B on the proliferative response of rat ventral prostate to 4 x 10-7 M testosterone following four days of culture in serum-free medium are shown in Figure 4 . At 4 x 10 -9 and 4 x 10 -7 M, oestradiol-17,B significantly (P<0.01) reduced the testosterone effect and was markedly inhibitory (P<0.01) at 4 x 1O-M. In contrast, the estramustine compounds were consistently less effective than oestradiol-17/ at all concentrations used.
Using the same procedure, Figure 5 demonstrates the effects of 4 x 10 -9, 4 x 10-7 and 4 x 10 5M Estracyt, Emeyt, estramustine and oestradiol-17/B on the proliferative response to 4 x 10 -9M testosterone, which is the minimum dose of testosterone for maximum stimulation of I-UdR uptake in serum-free cultures of rat ventral prostate (Mistry et al., 1982) . Treatment with 4 x 10-9 and 4 x 10 M oestradiol-17(3 reduced the testosterone response to the level of the testosterone-free controls (P < 0.01), whereas equimolar concentrations of the estramustine compounds were less effective. At 4x1-0M, Estracyt, Emcyt, and estramustine also reduced the testosterone response to control levels but treatment with 4 x 10-I M oestradiol-1 7/ remained more inhibitory. Pre-treatment with the estramustine compounds (4x 10 -5M) for 48h before the addition of 4x 10 -9 testosterone did not enhance the inhibitory actions of these drugs, and oestradiol-17/3 remained the most potent inhibitor of the testosterone response ( Figure 6 ).
Histology Histologically, cultures treated with 4 x 10-7 M testosterone alone or in combination with 4 x 10 -M Estracyt, Emcyt or estramustine in serum-free medium all showed well maintained, actively secreting alveolar epithelium. However, similar cultures treated with 4 x 10-7 M testosterone and 4 x 10 M oestradiol-17/3 exhibited extensive epithelial and stromal necrosis. Cultures treated with only 4 x 10 -9 M testosterone were well-preserved ( Figure 7A ), but the addition of 4 x O-M Estracyt ( Figure 7B ), Emcyt or estramustine caused epithelial atrophy. However, treatment with 4 x 10-7 M oestradiol-1 7p also produced severe epithelial regression ( Figure 7C ) and 4 x 10-I M oestradiol-17# remained cytotoxic. 
Discussion
While several studies have demonstrated inhibitory effects of Estracyt on prostatic DNA synthesis (Forsberg & Hoisaeter, 1975; Hoisaeter, 1975 Hoisaeter, , 1976b Hoisaeter, , 1977 al., 1983). In the present study, treatment with 4 x 10M Estracyt, estramustine and oestradiol-17/3 in serum supplemented medium all had equally inhibitory effects on 4 x 10-6M testosterone induced I-UdR uptake, whereas in serum-free medium only oestradiol-17/3 was effective in suppressing the response to testosterone. The histological results further demonstrated that the estramustine compounds had no antiprostatic effect in serum-free medium, but were cytotoxic in the presence of serum. In contrast, treatment with oestradiol-17/ was markedly cytotoxic in serum free medium, whereas it had an antiandrogenic effect causing epithelial atrophy in the presence of serum. Thus, serum appears to potentiate the antiprostatic activity of the estramustine compounds, while it reduces the inhibitory action of oestradiol-17#. The presence of steroid hormone binding proteins in the serum supplement may be responsible for eliminating the cytotoxic effect of oestradiol-17/3 and reducing the magnitude of the inhibitory effect on 1-UdR uptake by decreasing the concentration of free oestrogen in the medium. Similarly, the presence of steroid binding proteins may account for slight reductions in the stimulatory effect of testosterone on I-UdR uptake in serum supplemented cultures. However, the results did not indicate that increasing serum concentrations further affected the actions of either testosterone or oestradiol-17#.
In contrast to the present study, Hoisaeter (1975) found that in organ cultures of rat ventral prostate maintained in serum-supplemented medium (5% FCS) containing 4 x 10-6M testosterone and either 4 x 10-I M Estracyt or oestradiol-177#, only Estracyt had a significantly inhibitory effect on 3H-TdR uptake. Nevertheless, the histological results were remarkably similar to the present study, indicating that Estracyt had a pronounced cytotoxic effect on rat ventral prostate cultured in serum-supplemented medium while the retrogressive changes associated with oestradiol-17/3 were less severe. Unlike the present study, however, the morphology of cultures maintained in the absence of exogenous testosterone was comparable to intact tissue and did not demonstrate epithelial atrophy typical of androgen deprivation (Hoisaeter, 1975) . Moreover, Hoisaeter (1975) testosterone and this was attributed to a masking effect caused by endogenous hormones present in the serum supplement. While variations in the hormone content of different batches of foetal calf serum (Esber et al., 1973) may be responsible for these contrasting results, the present study further suggests that serum supplementation obscures differences between the effect of oestradiol-17/3 and its alkylated analogues.
Subsequent investigations using only serum-free medium showed that oestradiol-1 7/ remained consistently more effective than any of the estramustine compounds in suppressing testosterone induced I-UdR uptake. Oestradiol-17# exhibited dose-related inhibitory effects on both 4 x 10'7 and due to the release of some oestradiol-17/ from the hormone cytotoxic complex. Although Hoisaeter (1975) did not detect any hydrolysis of Estracyt by rat ventral prostate in organ culture, more recently Symes & Milroy (1982) found that the cleavage rate of estramustine by prostatic tissue in vitro is low but it is nevertheless, dose dependent, being greater at 10-5 than 10-8M. The inhibitory effects described with compounds in the range of 1O-9-1O-8 M would be in the physiological range of concentrations. Steady state concentrations of estramustine in the plasma are of a similar range to those used in these experiments (10-8 -1O-7 M) (HartleyAsp & Gunnarsson, 1982) .
While the oestradiol-17,B released upon hydrolysis of Estracyt probably contributes to the antiprostatic activity of this drug (Sandberg, 1983) , a purely oestrogenic mode of action for Estracyt probably contributes to the antiprostatic activity of this drug (Sandberg, 1983) , a purely oestrogenic mode of action for Estracyt has been discounted on evidence of anti-tumour activity in oestrogen relapsed prostatic cancer patients Madajewicz et al., 1980; Leistenschneider & Nagel, 1980) and in oestrogen resistant animal tumours (Muntzing et al., 1979) . In vitro studies of hormone unresponsive prostatic cancer cells (DU 145) further suggest that estramustine is the biologically active form of Estracyt (Hartley-Asp & Gunnarsson, 1982; HartleyAsp, 1984) , however recent organ culture studies of human prostatic cancer tissue showed that DNA synthesis was equally inhibited by oestradiol-17/3 and estramustine (Mistry et al., 1983) . Moreover, the present in vitro system indicates that neither Estracyt nor its metabolite, estramustine, offer any selective advantage over that of their carrier-hormone, oestradiol-17/ in suppressing testosterone-induced DNA synthesis in rat ventral prostate. Nevertheless, enhancement in the antiprostatic acitivty of the estramustine compounds in the presence of serum in vitro suggests that these drugs require biological activation for maximum efficacy.
